Level D· Scientific groundwork from lab and animal studiesLaboratory StudyEurope PMCOpen access

Ultra-Fine 3D Bioprinting of Dynamic Hyaluronic Acid Hydrogel for in Vitro Modeling

Tavakoli S., Kocatürkmen A., Oommen OP., Varghese OP.

Laboratory Study on Osteoarthritis, Immune Modulation, published in Adv Mater (2025) — summary generated from the PubMed abstract.

Open my reading list
Level D· Scientific groundwork from lab and animal studiesEvidence level of this study

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

  • Level A · Stronger Clinical Evidence
  • Level B · Emerging clinical evidence with positive signals
  • Level C · Early human research exploring benefits
  • Level D · Scientific groundwork from lab and animal studies
  • Emerging · Emerging topic under active research
Read the A–D evidence level guide

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Laboratory Study
Journal
Adv Mater (2025)
Reported sample size
—
Source database
Europe PMC
PMID
40357760
PMCID
PMC12306391
DOI
10.1002/adma.202500315
Citations
17

Abstract (original English)

3D bioprinting bridges tissue engineering and additive manufacturing, however developing bioinks with balanced biological and physical properties remains a challenge. Hyaluronic acid (HA) is a promising base material due to its biocompatibility and cell-recognition features. An HA-based bioink is designed using dynamic disulfide-crosslinking at physiological pH by modifying HA with cysteine moieties. To overcome the slow gelation kinetics typical of disulfide-crosslinked hydrogels, potassium iodide (KI) is introduced, accelerating gelation in a concentration-dependent manner. KI not only enhances gelation but also provides radical scavenging properties while maintaining hydrogel integrity. A low KI concentration (50 mm) offers more than a 3 h printing window, ensures cell viability, and facilitates the use of fine needles (32G, 108 µm inner diameter). This enables the fabrication of large (>3 cm) and complex 3D structures. Using this bioink, an osteoarthritis disease model is developed to investigate interactions between human mesenchymal stromal cells (hMSCs) and chondrocytes, demonstrating the immunomodulatory effect of hMSCs on inflammation-induced chondrocytes. Overall, the HA-based bioink addresses critical challenges in 3D bioprinting, providing a robust platform for constructing innovative in vitro models and supporting advancements in disease modeling and precision medi

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.
  • • This is preclinical work; animal or laboratory results cannot be applied to humans.

Evidence level

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

How we grade evidence
ChondrocytesMesenchymal Stem CellsHumansHyaluronic AcidBiocompatible MaterialsHydrogelsTissue EngineeringCell SurvivalBioprintingPrinting, Three-Dimensional

Browse all related research

Filter the research library by this study's title keywords, author, or publication year.

Related research